crystal51 / Shutterstock.com
Recent changes to patent law in China sees registration, review and litigation fall in line with established international IP systems, say Venable partners Keith Haddaway and Christopher Loh.
On June 1, 2021, the fourth amendment of the Chinese patent law went into effect. The amendment contains generally applicable provisions and makes specific changes to design patent law and Life Science-related patents.
Alongside this, the Chinese National Intellectual Property Administration (CNIPA) issued revised patentability guidelines in January 2021 directed to patent prosecution in the Life Sciences.
Fourth amendment – linkage system
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Patents, life sciences, litigation, CNIPA, design law, Hatch Waxman, biologics, medical use, statutory damages, novelty, invention